Cancer and Metastasis Reviews

, Volume 11, Issue 2, pp 121–139 | Cite as

Apoptosis induced by anticancer drugs

  • John A. Hickman


Most of the cytotoxic anticancer drugs in current use have been shown to induce apoptosis in susceptible cells. The fact that disparate agents, which interact with different targets, induce cell death with some common features (endonucleolytic cleavage of DNA, changes in chromatin condensation) suggests that cytotoxicity is determined by the ability of the cell to engage this so-called ‘programmed’ cell death. The mechanism of the coupling of a stimulus (drug-target interaction) to a response (cell death) is not known, but modulation of this coupling may affect the outcome of drug treatment. This review surveys the recent evidence which supports the idea that the drug-target interaction per se is not the sole determinant of cellular sensitivity of cytotoxic drugs. Studies of the signals which might engage apoptosis, the genes which modulate it and the biochemical process of drug-induced apoptosis itself are described, where possible, for glucocorticoids, topoisomerase inhibitors, alkylating agents, antimetabolites and antihormones. It is suggested that identification of the gene products which couple the stimulus to the response, and so determine intrinsic cellular sensitivity (and resistance), will be important targets for new types of drugs. These might then allow responses to occur in the major cancers of man, which are chemoresistant.

Key words

apoptosis cell death drugs antineoplastic drug resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Impact of the National Cancer Act: J Natl Cancer Inst 83: 1783–1796, 1991Google Scholar
  2. 2.
    Kessel D: Resistance to antineoplastic drugs. CRC Press. Boca Raton, FL, 1988Google Scholar
  3. 3.
    Dive C, Hickman JA: Drug target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192–196, 1991Google Scholar
  4. 4.
    Kung AL, Zetterberg A, Sherwood SW, Schimke RT: Cytotoxic effects of cell cycle phase specific agents: results of cell cycle perturbation. Cancer Res 50: 7307–7317, 1990Google Scholar
  5. 5.
    Cotter TG, Lennon SV, Martin SJ: Apoptosis: programmed cell death. J Biomed Sci 1: 72–80, 1990Google Scholar
  6. 6.
    Parris CN, Walker MC, Masters JR, Arlett CF: Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies. Cancer Res 50: 7513–7518, 1990Google Scholar
  7. 7.
    Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592–6595, 1991Google Scholar
  8. 8.
    O'Connor PM, Wassermann K, Sarang M, Magrath I, Bohr VA, Kohn KW: Relationship between DNA cross links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51: 6550–6557, 1991Google Scholar
  9. 9.
    Yonich-Roach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6. Nature (London) 352: 345–347, 1991Google Scholar
  10. 10.
    Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (London) 335: 440–442, 1988Google Scholar
  11. 11.
    Hockenbery D, Nunez G, Milliman RD, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial protein that blocks programmed cell death. Nature (London) 348: 334–336, 1990Google Scholar
  12. 12.
    Tsujimoto Y: Stress-resistance conferred by high level of bcl-2α protein in human B lymphoblastoid cell. Oncogene 4: 1331–1336, 1989Google Scholar
  13. 13.
    Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spandidos DA: Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 56: 251–259, 1987Google Scholar
  14. 14.
    Askew DS, Ashmun RA, Simmonds BC, Cleveland JL: Constitutive c-myc in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915–1922, 1991Google Scholar
  15. 15.
    Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128, 1992Google Scholar
  16. 16.
    Bertrand R, Sarang M, Jenkin J, Kerrigan D, Pommier Y: Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51: 6280–6285, 1991Google Scholar
  17. 17.
    Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res 50: 3748–3753, 1991Google Scholar
  18. 18.
    Buttyan R, Zakeri Z, Lockshin R, Wolgemuth D: Cascade of induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 2: 650–657, 1988Google Scholar
  19. 19.
    Yuh Y-S, Thompson EB: Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. J Biol Chem 264: 10904–10910, 1989Google Scholar
  20. 20.
    Alnemri ES, Fernandes TF, Haldar S, Croce CM, Litwack G: Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer Res 52: 491–495, 1992Google Scholar
  21. 21.
    Vogelstein B: Cancer. A deadly inheritance. Nature (London) 348: 681–682, 1990Google Scholar
  22. 22.
    Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311, 1991Google Scholar
  23. 23.
    Lau CC, Pardee AB: Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79: 2942–2946, 1982Google Scholar
  24. 24.
    Cohen JJ: Lymphocyte death induced by glucocorticoids. In: Schleimer RP, Claman HN, Oronsky AL (eds.) Antiinflammatory steroid action. Basic and Clinical Aspects. Academic Press, San Diego pp 110–131, 1989Google Scholar
  25. 25.
    Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 284: 555–556, 1980Google Scholar
  26. 26.
    Dyson JE, Simmons DM, Daniel J, McLaughlin JM, Quirke P, Bird CC: Kinetic and physical studies of cell death induced by chemotherapeutic agents or hyperthermia. Cell Tissue Kinet 19: 311–324, 1986Google Scholar
  27. 27.
    Compton MM, Cidlowski JA: Thymocyte apoptosis. A model of programmed cell death. Trends Endocrinol Metab 3: 17–23, 1992Google Scholar
  28. 28.
    Wyllie AH, Morris RG, Smith AC, Dunlop D: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67–77, 1984Google Scholar
  29. 29.
    Cohen JJ, Duke RC: Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 132: 38–42, 1984Google Scholar
  30. 30.
    Compton MM, Cidlowski JA: Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology 118: 38–45, 1986Google Scholar
  31. 31.
    Compton MM, Cidlowski JA: Identification of a glucocorticoid-induced nuclease in thymocytes. J Biol Chem 262: 8288–8292, 1987Google Scholar
  32. 32.
    Alnemri ES, Litwack G: Glucocorticoid-induced lymphocytolysis is not mediated by an induced endonuclease. J Biol Chem 264: 4101–4111, 1989Google Scholar
  33. 33.
    Schartzman RA, Cidlowski JA: Internucleosomal deoxyribonucleic acid cleavage activity in apoptotic thymocytes: detection and endocrine regulation. Endocrinology 128: 1190–1197, 1991Google Scholar
  34. 34.
    Hewish DR, Burgoyne LA: The calcium-dependent endonuclease of isolated nuclear preparations. Relationships between its occurrence and the occurrence of other classes of enzymes found in nuclear preparations. Biochem Biophys Res Commun 52: 475–481, 1973Google Scholar
  35. 35.
    Vanderbilt JN, Bloom KS, Anderson JN: Endogenous nuclease: properties and effects on transcribed genes in chromatin. J Biol Chem 257: 13009, 1982Google Scholar
  36. 36.
    Gaido ML, Cidlowski JA: Identification, purification, and characterization of a calcium-dependet endonuclease (NUC18) from apoptotic rat thymocytes. J Biol Chem 266: 18580–18585, 1991Google Scholar
  37. 37.
    Baxter GD, Smith PJ, Lavin MF: Molecular changes associated with induction of cell death in a human T-cell leukemia line: putative nucleases identified as histones. Biochem Biophys Res Commun 162: 30–37, 1989Google Scholar
  38. 38.
    Cerutti PA, Trump BT: Inflammation and oxidative stress in carcinogenesis. Cancer Cells 3: 1–7, 1991Google Scholar
  39. 39.
    Farzaneh F, Feon S, Lebby RA, Brill D, David JC, Shall S: DNA repair in human promyelocytic cell line, HL-60. Nucleic Acids Res 15: 3503–3513, 1987Google Scholar
  40. 40.
    Wielckens K, Delfs T: Glucocorticoid-induced cell death and poly[adenosine diphosphate (ADP)-ribosyl]ation: increased toxicity of dexamthassone on mouse S49.1 lymphoma cells, with the poly (ADP-ribosyl)ation inhibitor benzamide. Endocrinology 119: 2383–2392, 1986Google Scholar
  41. 41.
    Berger NA, Berger SJ, Sudar DC, Distelhorst CW: Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells. J Clin Invest 79: 1558–1563, 1987Google Scholar
  42. 42.
    Harmon JM, Thompson EB: Glucocorticoid resistance in leukemic cells. In: Resistance to antineoplastic drugs ed Kessel D, CRC press Inc, Boca Raton, FL, 1989Google Scholar
  43. 43.
    Zawydiwski R, Harmon JM, Thompson EB: Glucocorticoid-resistant human acute lymphoblastic leukemic cell line with functional receptor. Cancer Res 43: 3865–3873, 1983Google Scholar
  44. 44.
    Yuh Y-S, Thompson EB: Complementation between glucocorticoid receptor and lymphocytolysis in somatic cell hybrids of two glucocorticoid-resistant human leukemic clonal cell lines. Somat Cell Mol Gen 13: 33–46, 1987Google Scholar
  45. 45.
    Dieken ES, Miesfield RL: Transcriptional transactivation functions localized to the glucocorticoid receptor N terminus are necessary for steroid induction of lymphocyte apoptosis. Mol Cell Biol 12: 589–597, 1992Google Scholar
  46. 46.
    Nazareth LV, Harbour DV, Thompson EB: Mapping the human glucocorticoid receptor for leukemic cell death. J Biol Chem 266: 1276–12980, 1991Google Scholar
  47. 47.
    Beato M: Gene regulation by steroid hormones. Cell 56: 335–344, 1989Google Scholar
  48. 48.
    Goldstone SD, Lavin MF: Isolation of a cDNA clone, encoding a human beta-galactoside binding protein overexpressed during glucocorticoid-induced cell death. Biochem Biophys Res Commun 178: 746–750, 1991Google Scholar
  49. 49.
    Harrigan MT, Baughman G, Campbell NF, Bourgeois S: Isolation and characterization of glucocorticoid-and cyclic AMP-induced genes in T-lymphocytes. Mol Cell Biol 9: 3438–3446, 1989Google Scholar
  50. 50.
    Baughman G, Harrigan MT, Campbell NF, Nurrish SJ, Bourgeois S: Genes newly identified as regulated by glucocorticoids in murine thymocytes. Mol Endocrinol 5: 637–644, 1991Google Scholar
  51. 51.
    Dowd DR, MacDonald PN, Komm BS, Haussler MR, Miesfield R: Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J Biol Chem 266: 18423–18426, 1991Google Scholar
  52. 52.
    Eastman-Reks SB, Vedeckis WA: Glucocorticoid inhibition of c-myc, c-myb, and c-Ki-ras expression in a mouse lymphoma cell line. Cancer Res 46: 2457–2462, 1986Google Scholar
  53. 53.
    Reiss K, Fereber A, Travali S, Porcu P, Phillips PD, Baserga R: The protooncogene c-myb increases the expression of insulin-like growth factor I and insulin-like growth factor I receptor messenger RNAs by a transcriptional mechanism. Cancer Res 51: 5997–6000, 1991Google Scholar
  54. 54.
    Thulasi R, Harbour DV, Thompson EB: Suppression of c-myc gene expression is key step in glucocorticoid action of cell growth inhibition and lysis in human leukemic cell line CEM-C7. Proc Amer Assoc Cancer Res 32: 284, 1991Google Scholar
  55. 55.
    McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH, Orrenius S: Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys 269: 365–370, 1989Google Scholar
  56. 56.
    Tsien RY, Pozzan T, Rink TJ: cell mitogens cause early changes in cytoplasmic free Ca2+ and membrane potential in lymphocytes. Nature (London) 295: 68–71, 1982Google Scholar
  57. 57.
    McConkey DJ, Hartzell P, Jondal M, Orrenius S: Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J Biol Chem 264: 13399–13402, 1989Google Scholar
  58. 58.
    Lotem J, Cragoe EJ, Sachs L: Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 78: 953–960, 1991Google Scholar
  59. 59.
    Smith AC, Williams GT, Kingston R, Jenkinson EJ, Owen JJT: Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature (London) 337: 181–184, 1989Google Scholar
  60. 60.
    Bansal N, Houle AG, Melnykovych G: Dexamethasoneinduced killing of neoplastic cells of lymphoid derivation: lack of early calcium involvement. J Cell Physiol 143: 105–109, 1990Google Scholar
  61. 61.
    Thompson EA: Insensitivity to the cytolytic effects of glucocorticoids in vivo is associated with a novel ‘slow death’ phenotype. Cancer Res 51: 5544–5550, 1991Google Scholar
  62. 62.
    Lennon SV, Kilfeather SA, Hallet MB, Campbell AK, Cotter TG: Elevations of cytosolic free Ca2+ are not required to trigger apoptosis in human leukeamia cells. Clin Exp Immunol (in press)Google Scholar
  63. 63.
    McConkey DI, Hartzell P, Duddy SK, Hakansson H, Orrenius S: 2,3,7,8-Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca2+-mediated endonuclease activation. Science (Washington) 242: 256–259, 1988Google Scholar
  64. 64.
    Zacharchuk CM, Mercep M, Chakraborti PK, Simons SSJr, Ashwell JD: Programmed T lymphocyte death. Cell activation-and steroid-induced pathways are mutually antagonistic. J Immunol 145: 4037–4045, 1990Google Scholar
  65. 65.
    Nieto MA, Lopez-Rivas A: IL-2 protects T lymphocytes from glucocorticoid-induced DNA fragmentation and cell death. J Immunol 143: 4166–4170, 1989Google Scholar
  66. 66.
    Thompson EA: Glucocorticoid insensitivity of P1798 lymphoma cells is associated with production of a factor that attenuates the lytic response. Cancer Res 51: 5551–5556, 1991Google Scholar
  67. 67.
    Madden EA, Bishop EJ, Fiskin AM, Melnykovych G: Possible role of cholesterol in the susceptibility of a human acute lymphoblastic cell line to dexamethasone. Cancer Res 46: 617–622, 1986Google Scholar
  68. 68.
    Cults JL, Melnykovych G: The role of cholesterol in the glucocorticoid-mediated inhibition of cell cycle progression in human acute lymphoblastic leukemia cells. Exp Cell Res 168: 95–104, 1987Google Scholar
  69. 69.
    Bulva CJ, Printen J, Melnykovych G, Cults L, Barisas BG, Roess DA: Corticosteroid effects on lipid lateral diffusion in CEM-C1 and CEM-C7 acute lymphoblastic leukemia cells. Biochim Biophys Acta 1094: 134–137Google Scholar
  70. 70.
    Parikh DB, Melnykovych G: Increased dolichol content in glucocorticoid-sensitive human T-cell leukemia line grown in presence of dexamethasone. Biochem Biophys Res Commun 158: 163–169, 1989Google Scholar
  71. 71.
    Gewirtz DA: Does bulk damage to DNA explain the cytotoxic effects of topoisomerase inhibitors? Biochem Pharmacol 42: 2253–2258, 1991Google Scholar
  72. 72.
    Zwelling LA: Topoisomerase II as a target of antileukemic drugs: a review of controversial areas. Human Pathol 3: 101–112, 1989Google Scholar
  73. 73.
    Long BH, Musial ST, Brattain MG: Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16–213 and VM26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188, 1984Google Scholar
  74. 74.
    Loike JD, Horwitz SB: Effect of VP-16–213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15: 5443–5448, 1987Google Scholar
  75. 75.
    Villeponteau B, Pribyl TM, Grant MH, Martinson HG: Novobiocin induces the in vivo cleavage of active gene sequences in intact cells. J Biol Chem 261: 10359–10365, 1986Google Scholar
  76. 76.
    Jaxel C, Taudou G, Portemer C, Mirambeau G, Panijel J, Duguet M: Topoisomerase inhibitors induce irreversible fragmentation of replicated DNA in conconavalin A stimulated splenocytes. Biochemistry 27: 95–99, 1988Google Scholar
  77. 77.
    Kaufmann H: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870–5878, 1989Google Scholar
  78. 78.
    DelBino G, Darzynkiewicz Z: Camptothecin, teniposide, or 4′-(9-acridinylamino)-3-methansulfon-m-anisidine, but not mitoxanthrone or doxorubicin, induces degradation of nuclear DNA in the S-phase of HL-60 cells. Cancer Res 51: 1165–1169, 1991Google Scholar
  79. 79.
    Bertrand R, Kerrigan D, Sarang M, Pommier Y: Cell death induced by topoisomerase inhibitors. Role of calcium in mammalian cells. Biochem Pharmacol 42: 77–85, 1991Google Scholar
  80. 80.
    Zwelling LA, Altschuler E, Cherif A, Farquhar D: N-(5,5-diacetoxypentyl) doxorubicin: a novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res 51: 6704–6707, 1991Google Scholar
  81. 81.
    Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M: Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51: 1078–1085, 1991Google Scholar
  82. 82.
    Kyprianou N, Alexander RB, Isaacs JT: Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst 83: 346–350, 1991Google Scholar
  83. 83.
    Alnemri ES, Litwack G: Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. Evidence for a non-Ca2+-requiring mechanism(s). J Biol Chem 265: 17323–17333, 1990Google Scholar
  84. 84.
    Martin SJ, Lennon SV, Bonham AM, Cotter TG: Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNa or protein synthesis. J Immunol 145: 1859–1867, 1990Google Scholar
  85. 85.
    Collins RJ, Harmon BV, Souvlis T, Pope H, Kerr JFR: Effects of cycloheximide on B-chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis. Br J Cancer 64: 518–522, 1991Google Scholar
  86. 86.
    Shimizu T, Kubota M, Tanizawa A, Sano H, Kasai Y, Hashimoto H, Akiyama Y, Mikawa H: Inhibition of both etoposide-induced DNA fragmentation and activation of poly(ADP-ribose) synthesis by zinc ion. Biochem Biophys Res Commun 69: 1172–1177, 1990Google Scholar
  87. 87.
    Kaufmann SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129–1136, 1991Google Scholar
  88. 88.
    Dive C, Gregory CD, Phipps DJ, Evans DL, Milner AE, Wyllie AH: Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim Biophys Acta 1133: 275–285, 1992Google Scholar
  89. 89.
    Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PE, Haslett C: Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83: 865–875, 1989Google Scholar
  90. 90.
    Fesus L, Thomazy V, Autori A, Ceru MP, Tarsca E, Piacentini M: Apoptotic hepatocytes becomes insoluble in detergents and chaotropic agents as a result of transglutaminase action. FEBS Letters 245: 150–154, 1989Google Scholar
  91. 91.
    Lock RB, Ross WE: Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in chinese hamster ovary cells. Cancer Res 50: 3761–3766, 1990Google Scholar
  92. 92.
    Hirano T, Funahashi S, Uemura T, Yanagida M: Isolation and characterization of Schizosaccharomyces pombe cut mutants that block nuclear division but not cytokinesis. EMBO J 5: 2973–2979, 1986Google Scholar
  93. 93.
    Weinert TA, Hartwell LH: The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science (Washington) 241: 317–322, 1988Google Scholar
  94. 94.
    Rubin E, Kharbanda S, Gunji H, Kufe D: Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol 39: 697–701, 1991Google Scholar
  95. 95.
    Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cyele arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749–755, 1990Google Scholar
  96. 96.
    Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmac 40: 2353–2362, 1990Google Scholar
  97. 97.
    Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275–280, 1990Google Scholar
  98. 98.
    Mares V, Schereni E, Biggiogera M, Bernocchi G: Influence of cis-dichlorodiammineplatinum on the structure of the immature rat cerebellum. Exp Neurol 91: 246–258, 1986Google Scholar
  99. 99.
    Biggiogera M, Scherini E, Mares V: Ultrastructural cytochemistry of cis-dichlorodiammineplatium II induced apoptosis in immature rat cerebellum. Acta Histochem Cytochem 23: 831–839, 1990Google Scholar
  100. 100.
    Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science (Washington) 246: 629–633, 1989Google Scholar
  101. 101.
    Sorenson CM, Eastman A: Influence of cis-diammined-ichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48: 6703–6707, 1988Google Scholar
  102. 102.
    Lennon SV, Martin SJ, Cotter TG: Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 24: 203–214, 1991Google Scholar
  103. 103.
    Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JFR: An electron microscopical study of the mode of cell death induced by cancer chemotherapeutic agents in populations of normal and neoplastic cells. J Pathol 116: 129–138, 1975Google Scholar
  104. 104.
    Kwok JBJ, Tattersall MHN: Inhibition of 2-desamino-2-methyl-10-propargyl-5,8-dideazatetrahydrofolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools. Biochem Pharmac 42: 505–513, 1991Google Scholar
  105. 105.
    Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hiroto Y, Ayusawa D, Seno T, Garret C, Wataya Y: Deoxyribonucleoside-triphosphate imbalance. 5-Fluorodeoxyuridineinduced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 262: 8235–8241, 1987Google Scholar
  106. 106.
    Curtin NJ, Harris AL, Aherne GW: Mechanism of cell death following thymidylate synthase inhibition: 2′-deox-yuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 51: 2346–2352, 1991Google Scholar
  107. 107.
    Lorico A, Toffoli G, Boiocchi M, Erba E, Broggini M, Rappa G, D'Incalci M: Accumulation of DNA strand breaks in cells exposed to methotrexate or N 10-propargyl-5,8-dideazafolic acid. Cancer Res 48: 2036–2041, 1988Google Scholar
  108. 108.
    Li JC, Kaminskas E: Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res 47: 2755–2758, 1987Google Scholar
  109. 109.
    Gunji H, Kharbanda S, Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 51: 741–743, 1991Google Scholar
  110. 110.
    Kyprianou N, English HF, Davidson NE, Isaacs JT: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162–166, 1991Google Scholar
  111. 111.
    Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and antiprogestin in breast cancer cells. Cancer Res 47: 1441–1448, 1987Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • John A. Hickman
    • 1
  1. 1.CRC Molecular and Cellular Pharmacology Group, School of Biological SciencesUniversity of ManchesterManchesterUK

Personalised recommendations